Kumar Sachin, Ranga Abhishek
Department of Pharmacology, DIPSAR, Delhi Pharmaceutical Sciences and Research University, New Delhi, India.
Biofactors. 2025 Jan-Feb;51(1):e2146. doi: 10.1002/biof.2146. Epub 2024 Nov 27.
Breast cancer, a complex and heterogeneous ailment impacting numerous women worldwide, persists as a prominent cause of cancer-related fatalities. MicroRNAs (miRNAs), small non-coding RNAs, have garnered significant attention for their involvement in breast cancer's progression. These molecules post-transcriptionally regulate gene expression, influencing crucial cellular processes including proliferation, differentiation, and apoptosis. This review provides an overview of the current research on the role of miRNAs in breast cancer. It discusses the role of miRNAs in breast cancer, including the different subtypes of breast cancer, their molecular characteristics, and the mechanisms by which miRNAs regulate gene expression in breast cancer cells. Additionally, the review highlights recent studies identifying specific miRNAs that are dysregulated in breast cancer and their potential use as diagnostic and prognostic biomarkers. Furthermore, the review explores the therapeutic potential of miRNAs in breast cancer treatment. Preclinical studies have shown the effectiveness of miRNA-based therapies, such as antagomir and miRNA mimic therapies, in inhibiting tumor growth and metastasis. Emerging areas, including the application of artificial intelligence (AI) to advance miRNA research and the "One Health" approach that integrates human and animal cancer insights, are also discussed. However, challenges remain before these therapies can be fully translated into clinical practice. In conclusion, this review emphasizes the significance of miRNAs in breast cancer research and their potential as innovative diagnostic and therapeutic tools. A deeper understanding of miRNA dysregulation in breast cancer is essential for their successful application in clinical settings. With continued research, miRNA-based approaches hold promise for improving patient outcomes in this devastating disease.
乳腺癌是一种复杂且异质性的疾病,影响着全球众多女性,仍然是癌症相关死亡的主要原因。微小RNA(miRNA)作为小的非编码RNA,因其参与乳腺癌进展而备受关注。这些分子在转录后调控基因表达,影响包括增殖、分化和凋亡在内的关键细胞过程。本综述概述了当前关于miRNA在乳腺癌中作用的研究。它讨论了miRNA在乳腺癌中的作用,包括乳腺癌的不同亚型、它们的分子特征以及miRNA在乳腺癌细胞中调控基因表达的机制。此外,该综述强调了最近鉴定出在乳腺癌中失调的特定miRNA及其作为诊断和预后生物标志物的潜在用途的研究。此外,该综述探讨了miRNA在乳腺癌治疗中的治疗潜力。临床前研究表明基于miRNA的疗法,如抗miR和miRNA模拟疗法,在抑制肿瘤生长和转移方面的有效性。还讨论了新兴领域,包括应用人工智能(AI)推进miRNA研究以及整合人类和动物癌症见解的“同一健康”方法。然而,在这些疗法能够完全转化为临床实践之前,挑战仍然存在。总之,本综述强调了miRNA在乳腺癌研究中的重要性及其作为创新诊断和治疗工具的潜力。深入了解乳腺癌中miRNA的失调对于它们在临床环境中的成功应用至关重要。随着持续研究,基于miRNA的方法有望改善这种毁灭性疾病患者的预后。